Octaplex (Human Coagulation Factor Ix, Protein C, Human Coagulation Factor Vii, Protein S, Human Coagulation F)

Human Coagulation Factor IX in Octaplex restores the intrinsic pathway of the clotting cascade by providing the missing factor IX protein. This enables activation of factor X, leading to thrombin generation and fibrin clot formation, thereby correcting the bleeding tendency associated with factor IX deficiency.

The dose of Octaplex is individualized by the prescribing clinician based on the patient’s specific factor deficiency, severity of bleeding, body weight, and laboratory factor activity levels. Only a qualified healthcare professional should determine the appropriate dosing regimen.

Octaplex may be used during pregnancy or lactation only when the expected benefit to the mother outweighs potential risks to the fetus or infant. Clinicians should evaluate each case carefully and discuss possible effects with the patient before initiating therapy.

To request Octaplex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Octaplex is a multi‑component plasma‑derived concentrate containing factor IX, factor VII, protein C, protein S, and factor X, offering broader coverage than single‑factor products. This can be advantageous for patients with multiple deficiencies, whereas recombinant single‑factor concentrates target only one specific protein.

Octaplex must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, allow the vial to reach room temperature if required, and inspect for particulate matter or discoloration; discard if any abnormalities are observed.

Octaplex is supplied as a sterile injectable solution and is administered intravenously by a qualified healthcare professional. The infusion rate and volume are determined by the prescriber, and patients are monitored for any immediate adverse reactions during and after the infusion.

Serious risks include anaphylactic reactions, development of inhibitory antibodies against clotting factors, thromboembolic events, severe hypertension, hemolysis, and disseminated intravascular coagulation. Prompt recognition and medical intervention are essential if any of these events occur.

Octaplex is contraindicated in patients with known hypersensitivity to any of its protein components or to the excipients used in the formulation. It should also be avoided in individuals with a history of severe allergic reactions to plasma‑derived products unless the benefits clearly outweigh the risks.